UL16‑binding protein 1 is a significant prognostic and diagnostic marker for breast cancer

Zhang,Xiaowei; Dai,Shuhong; Li,Liang; Wang,Pengyun; Dong,Mingxin

doi:10.3892/ol.2024.14761

UL16‑binding protein 1 is a significant prognostic and diagnostic marker for breast cancer

Authors:
- Xiaowei Zhang
- Shuhong Dai
- Liang Li
- Pengyun Wang
- Mingxin Dong
View Affiliations

Affiliations: Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, Shandong 266023, P.R. China, Department of Cardiology, Zibo Central Hospital, Zibo, Shandong 255036, P.R. China, Department of Orthopedics, Zibo Central Hospital, Zibo, Shandong 255036, P.R. China
Published online on: October 21, 2024 https://doi.org/10.3892/ol.2024.14761
Article Number: 15
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the association between UL16 binding protein 1 (ULBP1) and the prognosis of patients with and immune cell infiltration in breast cancer (BRCA). The mRNA data of BRCA and immune‑related genes were extracted from The Cancer Genome Atlas and were analyzed using bioinformatics tools. Subsequently, the results obtained by bioinformatics were validated through the collection of clinical patient data at the Zibo Central hospital (Zibo, China). The difference in the expression of the ULBP1 gene between BRCA tissues and normal precancerous tissues was analyzed, followed by validation using immunohistochemistry. By combining clinical data from patients with BRCA, the prognostic and diagnostic significance of the ULBP1 gene in patients with BRCA was analyzed. Gene enrichment analysis was conducted to gain insight into the molecular mechanisms underlying the regulatory role of ULBP1 in BRCA by analyzing its related functions and signaling pathways. Furthermore, single sample gene set enrichment analysis (ssGSEA) and Spearman's correlation analysis were performed to explore the correlation between ULBP1 as a target gene related with tumor immune cell infiltration. The data revealed that ULBP1 is a target gene associated with immunity and the prognosis of patients with BRCA. Patients with BRCA with a high expression of ULBP1 had a poorer prognosis. ULBP1 expression correlated with progesterone receptor expression, estrogen receptor expression and histological type in patients with BRCA; thus, it may serve as an independent predictor for the overall survival rate of patients. Functional enrichment analysis revealed a significant co‑expression between ULBP1 and ULBP2, ULBP3, retinoic acid early transcript 1K, as well as a significant enrichment of pathways associated with carcinogenesis and immune suppression. ssGSEA and Spearman's correlation analysis demonstrated significant correlations between ULBP1 expression and tumor immune cells, as well as immune checkpoints. Overall, the present study demonstrated that ULBP1 was associated with BRCA immunity and might serve as a prognostic and diagnostic biomarker for patients with BRCA. In addition, it might also be a potential target for the immunotherapy of BRCA.

View Figures

View References

1	Wilkinson L and Gathani T: Understanding breast cancer as a global health concern. The Br J Radiol. 95:202110332022. View Article : Google Scholar
2	Kawiak A: Molecular research and treatment of breast cancer. Int J Mol Sci. 23:96172022. View Article : Google Scholar
3	Trapani D, Ginsburg O, Fadelu T, Lin NU, Hassett M, Ilbawi AM, Anderson BO and Curigliano G: Global challenges and policy solutions in breast cancer control. Cancer Treat Rev. 104:1023392022. View Article : Google Scholar
4	Ben-Dror J, Shalamov M and Sonnenblick A: The history of early breast cancer treatment. Genes (Basel). 13:9602022. View Article : Google Scholar
5	Katsura C, Ogunmwonyi I, Kankam HK and Saha S: Breast cancer: Presentation, investigation and management. Br J Hosp Med (Lond). 83:1–7. 2022. View Article : Google Scholar
6	Sarhangi N, Hajjari S, Heydari SF, Ganjizadeh M, Rouhollah F and Hasanzad M: Breast cancer in the era of precision medicine. Mol Biol Rep. 49:10023–10037. 2022. View Article : Google Scholar
7	Goel S and Chandarlapaty S: Emerging therapies for breast cancer. Cold Spring Harb Perspect Med. 13:a0413332023. View Article : Google Scholar
8	Lança T, Correia DV, Moita CF, Raquel H, Neves-Costa A, Ferreira C, Ramalho JS, Barata JT, Moita LF, Gomes AQ and Silva-Santos B: The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood. 115:2407–2411. 2010. View Article : Google Scholar
9	López-Soto A, Quiñones-Lombraña A, López-Arbesú R, López-Larrea C and González S: Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor. J Biol Chem. 281:30419–30430. 2006. View Article : Google Scholar
10	Hu B, Tian X and Li Y, Liu Y, Yang T, Han Z, An J, Kong L and Li Y: Epithelial-mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1. Cancer Med. 9:2686–2697. 2020. View Article : Google Scholar
11	Zuo J, Willcox BE and Moss P: ULBPs: Regulators of human lymphocyte stress recognition. Oncotarget. 8:106157–106158. 2017. View Article : Google Scholar
12	Ruan GT, Xie HL, Zhu LC, Ge YZ, Yan L, Liao C, Gong YZ and Shi HP: Immune ULBP1 is elevated in colon adenocarcinoma and predicts prognosis. Front Genet. 13:7625142022. View Article : Google Scholar
13	Easom NJW, Marks M, Jobe D, Gillmore R, Meyer T, Maini MK and Njie R: ULBP1 is elevated in human hepatocellular carcinoma and predicts outcome. Front Oncol. 10:9712020. View Article : Google Scholar
14	Cho H, Chung JY, Kim S, Braunschweig T, Kang TH, Kim J, Chung EJ, Hewitt SM and Kim JH: MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer. 14:9572014. View Article : Google Scholar
15	Wen WX, Soo JS, Kwan PY, Hong E, Khang TF, Mariapun S, Lee CS, Hasan SN, Rajadurai P, Yip CH, et al: Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. Breast Cancer Res. 18:562016. View Article : Google Scholar
16	Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 439:353–357. 2006. View Article : Google Scholar
17	Liu RZ, Graham K, Glubrecht DD, Germain DR, Mackey JR and Godbout R: Association of FABP5 expression with poor survival in triple-negative breast cancer: Implication for retinoic acid therapy. Am J Pathol. 178:997–1008. 2011. View Article : Google Scholar
18	Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, et al: Correlating transcriptional networks to breast cancer survival: A large-scale coexpression analysis. Carcinogenesis. 34:2300–2308. 2013. View Article : Google Scholar
19	Zhang X, Ruan Y, Li Y, Lin D and Quan C: Tight junction protein claudin-6 inhibits growth and induces the apoptosis of cervical carcinoma cells in vitro and in vivo. Med Oncol. 32:1482015. View Article : Google Scholar
20	Kamimura H, Yamagiwa S, Tsuchiya A, Takamura M, Matsuda Y, Ohkoshi S, Inoue M, Wakai T, Shirai Y, Nomoto M, et al: Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. J Hepatol. 56:381–388. 2012. View Article : Google Scholar
21	Lee GH, An HJ, Kim TH, Kim G, Park KS, Park H, Lee TH and Kwon AY: Clinical impact of natural killer group 2D receptor expression and that of its ligand in ovarian carcinomas: A retrospective study. Yonsei Med J. 62:288–297. 2021. View Article : Google Scholar
22	Liu X, Sun M, Yu S, Liu K, Li X and Shi H: Potential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cells. Onco Targets Ther. 8:3095–3104. 2015.
23	Bae JH, Kim SJ, Kim MJ, Oh SO, Chung JS, Kim SH and Kang CD: Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. Cancer Sci. 103:7–16. 2012. View Article : Google Scholar
24	Himmelreich H, Mathys A, Wodnar-Filipowicz A and Kalberer CP: Post-transcriptional regulation of ULBP1 ligand for the activating immunoreceptor NKG2D involves 3′ untranslated region. Hum Immunol. 72:470–478. 2011. View Article : Google Scholar
25	Nanbakhsh A, Pochon C, Mallavialle A, Amsellem S, Bourhis JH and Chouaib S: c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis. Blood. 123:3585–3595. 2014. View Article : Google Scholar
26	Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG and Cerwenka A: Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 71:5998–6009. 2011. View Article : Google Scholar
27	Odle TG: Precision medicine in breast cancer. Radiol Technol. 88:401M–421M. 2017.
28	Postow MA, Sidlow R and Hellmann MD: Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 378:158–168. 2018. View Article : Google Scholar
29	Zhang Y and Zheng J: Functions of immune checkpoint molecules beyond immune evasion. Adv Exp Med Biol. 1248:201–226. 2020. View Article : Google Scholar
30	Onkar SS, Carleton NM, Lucas PC, Bruno TC, Lee AV, Vignali DAA and Oesterreich S: The great immune escape: understanding the divergent immune response in breast cancer subtypes. Cancer discov. 13:23–40. 2023. View Article : Google Scholar
31	da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG and de Melo AC: Triple negative breast cancer: A thorough review of biomarkers. Crit Rev Oncol Hematol. 145:102855. 2020. View Article : Google Scholar
32	Dermani FK, Samadi P, Rahmani G, Kohlan AK and Najafi R: PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol. 234:1313–1325. 2019. View Article : Google Scholar